Radionuclide Imaging in Decision-Making for Coronary Revascularization in Stable Ischemic Heart Disease
Purpose of the Review
This review will discuss the current nuclear imaging techniques for defining ischemia and hibernation/viability, their advantages and disadvantages, and the data related to their use to direct revascularization decisions.
Recent interventional trials highlight the importance of functional imaging in trying to determine who may benefit from revascularization. Outcome benefit from revascularization has previously been shown in patients with significant ischemia, and flow quantification from positron emission tomography (PET) may allow for further risk stratification; similar data may soon be available with single-photon emission computed tomography (SPECT) as well using the newer cadmium-zinc-telluride (CZT) cameras. Some degree of equipoise still exists regarding the utilization of myocardial viability to guide revascularization in patients with ischemic cardiomyopathy, with recent studies presenting conflicting results.
There is a niche for radionuclide imaging in helping to guide revascularization decision-making, and advances in recent years are providing new mechanisms by which we may better clarify the particular circumstances in which it can and should be applied. However, most data at this time is limited to observational cohorts and inferences from other randomized trials. The results of upcoming trials like ISCHEMIA and AIMI-HF will hopefully provide the needed evidence to support current clinical practice, or may change our algorithms altogether.
KeywordsNuclear imaging Coronary revascularization Coronary artery disease Myocardial viability
Compliance with Ethical Standards
Conflict of Interest
Robert A deKemp reports grants from Canadian Institutes of Health Research during the conduct of the study, grants from Jubilant DraxImage outside the submitted work, and a patent Rubidium Generator Technologies licensed to Jubilant DraxImage. Rob SB Beanlands reports grants and personal honorarium from GE, Lantheus Medical Imaging, and Jubilant DRAXImage, outside the submitted work. All other authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.CrossRefPubMedGoogle Scholar
- 6.Fihn SD, Blankenship JC, Alexander KP, Bittl J a, Byrne JG, Fletcher BJ, et al. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography, and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;64:1929–49.CrossRefPubMedGoogle Scholar
- 10.Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–91.CrossRefPubMedGoogle Scholar
- 11.• Mielniczuk LM, Toth GG, Xie JX, De Bruyne B, Shaw LJ, Beanlands RS. Can functional testing for ischemia and viability guide revascularization? JACC Cardiovasc Imaging. 2017;10:354–64. Good review of the role of ischemia and viability testing in ischemic heart disease and expected contributions from ongoing trials. CrossRefPubMedGoogle Scholar
- 12.Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002–12.CrossRefPubMedGoogle Scholar
- 13.• Mc Ardle B, Shukla T, Nichol G, deKemp, RA, Bernick J, Guo A, et al. Long-term follow-up of outcomes with F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease. Circ Cardiovasc Imaging. 2016; 9. Long-term outome data highlighting the benefit of PET viability imaging in patients with suspected ischemic cardiomyopathy being considered for revascularization, provided there is adherence to PET recommendations. Circ Cardiovasc Imaging. 2016;9(9). pii: e004331. Google Scholar
- 26.Takx RA, Blomberg BA, El Aidi H, Habets J, de Jong PA, Nagel E, et al. Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis. Circ Cardiovasc Imaging. 2015;8(1). pii: e002666..Google Scholar
- 31.• Boiten HJ, van den Berge JC, Valkema R, van Domburg RT, Zijlstra F, Schinkel AF. Ischemia burden on stress SPECT MPI predicts long-term outcomes after revascularization in stable coronary artery disease. J Nucl Cardiol. 2018;25:958-66. This study supports previous findings by demonstrating a mortality benefit in patients with ischemia on SPECT MPI who undergo early revascularization, driven by those with moderate to severe ischemia burden. Google Scholar
- 32.Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107:2900–7.CrossRefPubMedGoogle Scholar
- 33.Hachamovitch R, Rozanski A, Hayes SW, Thomson LE, Germano G, Friedman JD, et al. Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary? J Nucl Cardiol. 2006;13:768–78.CrossRefPubMedGoogle Scholar
- 34.Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32:1012–24.CrossRefPubMedGoogle Scholar
- 38.Karthikeyan G, Guzic Salobir B, Jug B, Devasenapathy N, Alexanderson E, Vitola J, et al. Functional compared to anatomical imaging in the initial evaluation of patients with suspected coronary artery disease: an international, multi-center, randomized controlled trial (IAEA-SPECT/CTA study). J Nucl Cardiol. 2017;24:507–17.CrossRefPubMedGoogle Scholar
- 39.Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al. The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009;120:2529–40.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. J Nucl Cardiol. 2012;19:658–69.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.•• Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET: joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Med. 2018;59:273–93. New joint position paper on technical considerations and clinical applications of PET myocardial blood flow. CrossRefPubMedGoogle Scholar
- 47.Hajjiri MM, Leavitt MB, Zheng H, Spooner AE, Fischman AJ, Gewirtz H. Comparison of positron emission tomography measurement of adenosine-stimulated absolute myocardial blood flow versus relative myocardial tracer content for physiological assessment of coronary artery stenosis severity and location. JACC Cardiovasc Imaging. 2009;2:751–8.CrossRefPubMedGoogle Scholar
- 51.Gupta A, Taqueti VR, van de Hoef TP, Bajaj NS, Bravo PE, Murthy VL, et al. Integrated non-invasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation. 2017;136:2325–36.CrossRefPubMedGoogle Scholar
- 55.• Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015;131:19–27. Interesting trial in which MFR was associated with outcomes independent of angiographic CAD and also modified the effect of early revascularization, in particular demonstrating an outcome benefit with CABG in those with reduced MFR. CrossRefPubMedGoogle Scholar
- 57.van de Hoef TP, van Lavieren MA, Damman P, Delewi R, Piek MA, Chamuleau SA, et al. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. Circ Cardiovasc Interv. 2014;7:301–11.CrossRefPubMedGoogle Scholar
- 58.Feher A, Sinusas AJ. Quantitative assessment of coronary microvascular function: dynamic single-photon emission computed tomography, positron emission tomography, ultrasound, computed tomography, and magnetic resonance imaging. Circ Cardiovasc Imaging. 2017;10(8). pii: e006427.Google Scholar
- 59.• Ben Bouallegue F, Roubille F, Lattuca B, Cung TT, Macia JC, Gervasoni R, et al. SPECT myocardial perfusion reserve in patients with multivessel coronary disease: correlation with angiographic findings and invasive fractional flow reserve measurements. J Nucl Med. 2015;56:1712–7. Study demonstrating the ability to obtain flow quantification data with SPECT using a CZT camera and its good correlation with invasive angiographic findings. CrossRefPubMedGoogle Scholar
- 61.Bateman TM, Dilsizian V, Beanlands RS, DePuey EG, Heller GV, Wolinsky DA. American Society of Nuclear Cardiology and Society of nuclear medicine and molecular imaging joint position statement on the clinical indications for myocardial perfusion PET. J Nucl Med. 2016;57:1654–6.CrossRefPubMedGoogle Scholar
- 68.Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6:363–72.CrossRefPubMedGoogle Scholar
- 71.Abraham A, Nichol G, Williams KA, Guo A, deKemp RA, Garrard L, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2010;51:567–74.CrossRefPubMedGoogle Scholar
- 73.Zelt JGE, Liu PP, Erthal F, deKemp RA, Wells G, O’Meara E, et al. N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin T levels are related to the extent of hibernating myocardium in patients with ischemic heart failure. Can J Cardiol. 2017;33:1478–88.CrossRefPubMedGoogle Scholar
- 81.Lee JM, Bang JI, Koo BK, Hwang D, Park J, Zhang J, et al. Clinical relevance of (18)F-sodium fluoride positron-emission tomography in noninvasive identification of high-risk plaque in patients with coronary artery disease. Circ Cardiovasc Imaging. 2017;10(11). pii: e006704.Google Scholar
- 86.Betancur J, Otaki Y, Motwani M, Fish MB, Lemley M, Dey D, et al. Prognostic value of combined clinical and myocardial perfusion imaging data using machine learning. JACC Cardiovasc Imaging. 2017 Oct 16. pii: S1936-878X(17)30804-5.Google Scholar